Capecitabine, oxaliplatin

Phase 3Small molecule

PPeking Union Medical College Hospital

Capecitabine, oxaliplatin is one of 47 small molecule programs targeting Colorectal Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Colorectal CancerActive, not recruiting

Gastric CancerActive, not recruiting

Colorectal CancerPhase 3

Active, not recruiting

Gastric CancerPreclinical

Active, not recruiting

Competition

Competitive Landscape

949 competitors in Colorectal Cancer

#DrugCompanyPhaseTrials

Capecitabine, oxaliplatin

PPeking Union Medical College Hospital

Phase 3

3 2

Eylea

Regeneron

Preclinical

5 3

Emend IV

PORTRAZZA

Ketalar

AAultman Health Foundation

Preclinical

1 6

Versed

CConrado Roberto Hoffmann Filho

Preclinical

1 7

Ultiva

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

1 8

Bridion

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 9

Andriol

AAuxilium

Preclinical

1 10

Feraheme

AAzurity Pharmaceuticals

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Active, not recruiting

Complete Response

NCT03840239

Clinical

Trials by Indication[1]

Colorectal Cancer3 trials

Study of S-1 and Oxaliplatin (SOX) Versus Capecitabine and Oxaliplatin (COX) in Patients With Advanced Colorectal Cancer

Completed·SSamsung Medical Center·Phase 3·NCT00677443·344 enrolled

Phase II Trial Assessing Efficacy and Toxicity of Capecitabine and Oxaliplatin in the Treatment of Colorectal Cancer

Completed·RRoyal Marsden NHS Foundation Trust·Phase 2·NCT00220116·172 enrolled

Investigation of the Value of ctDNA in Diagnosis, Treatment, and Surveillance of Surgically Resectable Colorectal Cancer

Unknown status·PPeking Union Medical College Hospital·Phase 3·NCT03038217·300 enrolled

Gastric Cancer1 trial

Lymph Node Metastasis in Extended Lymphadenectomy for Gastric Cancer From a CLASSIC Trial

Completed·SSeoul National University Hospital··NCT02298010·899 enrolled

Locally-advanced Rectal Cancer1 trial

Preoperative Chemoradiation Followed by Chemotherapy for Locally Advanced Rectal Cancer

Unknown status·NNational Cancer Center, Korea·Phase 2·NCT01952951·110 enrolled

Gastroesophageal Junction1 trial

Apatinib Plus Concurrent Neoadjuvant Chemoradiotherapy for Gastroesophageal Junction

Unknown status·HHebei Medical University·Phase 3·NCT03986385·180 enrolled

Rectal Cancer With Liver Metastases1 trial

Preoperative CRT With or Without Induction Chemotherapy for Rectal Cancer With Liver Metastases

Completed·—·Phase 2·NCT01643070·38 enrolled

1 more indication

Complete Response1 trial

TNT to Increase the Clinical Complete Response Rate for Distal LARC

Active, not recruiting·SSun Yat-sen University·Phase 2·NCT03840239·98 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for Capecitabine, oxaliplatin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Capecitabine, oxaliplatin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Capecitabine, oxaliplatin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Peking Union Medical College Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: PPeking Union Medical College Hospital

Capecitabine, oxaliplatin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Colorectal Cancer3 trials

Gastric Cancer1 trial

Locally-advanced Rectal Cancer1 trial

Gastroesophageal Junction1 trial

Rectal Cancer With Liver Metastases1 trial

Complete Response1 trial

References

Drug Info

Quick Facts

Related News